The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

tearsolutions.com

Founded Year

2013

Stage

Convertible Note - IV | Alive

Total Raised

$28.43M

Last Raised

$5.62M | 4 mos ago

About TearSolutions

TearSolutions is a drug development company focused on dry eye. TearSolutions aims to advance tear generation therapy for dry eyes through phase II human clinical trials. The platform technology is centered on the tear protein lacritin​ and its proprietary drug Lacripep​.

TearSolutions Headquarter Location

315 Old Ivy Way Suite 301

Charlottesville, Virginia, 22903,

United States

434-951-0444

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing TearSolutions

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

TearSolutions is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Latest TearSolutions News

TearSolutions, Inc. Announces Outcome of Type C Meeting with FDA and Next Steps in the Development of Lacripep™

Feb 14, 2022

Charlottesville Virginia, UNITED STATES CHARLOTTESVILLE, Va., Feb. 14, 2022 (GLOBE NEWSWIRE) -- TearSolutions, Inc. (“the Company”), a privately held developer of a replacement therapy for the treatment of Dry Eye Disease (DED) called Lacripep, today announced that in late 2021 it received official minutes from a Type C meeting with the U.S. Food and Drug Administration (FDA) regarding the development of Lacripep for the treatment of keratoconjunctivitis sicca, also known as DED, and is planning to begin one of two phase III trials. Based on guidance the Company received, TearSolutions is preparing to conduct two phase III pivotal trials, one in a primary Sjögren’s Syndrome (pSS) patient population and the second in a potentially less severe general dry eye population. The first trial will be a multi-part Phase II/III trial where one study will be conducted in patients with DED associated with pSS to confirm results observed in the previously conducted Phase I/II trial and the other study will be in a general, potentially less severe, DED population. The second phase III trial is planned to be in a general DED population that will not exclude pSS patients. In addition, FDA provided guidance with regard to the study design for the first phase III, which has been incorporated into the trials’ preliminary design characteristics: Number of patients: approximately 240 Patient populations: pSS associated DED and general DED Primary endpoint: statistically significant improvement in both sign (inferior corneal fluorescein staining) and symptom (burning and stinging) as compared to baseline Visits: Screening/Baseline, Week 2, Week 4, Week 6 and safety follow-up over the course of one year The Company is currently planning the first phase III with targeted first enrollment in July 2022, for which the Company would expect top-line efficacy results from the general DED study in Q1 2023 and at the end of 2023 for the pSS DED study. The initiation and execution of the first phase III, beyond the start-up phase, is subject to additional funding or strategic partnering and may be further impacted by the COVID-19 pandemic. “We thank FDA for the constructive comments, guidance and support related to the continued development of Lacripep,” commented Marc Odrich, Chief Medical Officer. “The feedback from FDA and our advisors, along with the learnings from our Phase I/II first-in-human trial has us convinced that we are on a path to bringing a novel and disruptive therapy to the market in Lacripep, which has the potential to address significant unmet needs for the millions of people suffering from Dry Eye Disease.” About TearSolutions, Inc. TearSolutions is a privately held biotechnology company focused on the discovery, development and commercialization of novel therapies for the treatment of patients with DED. The Company is based in Charlottesville, VA. The Company is currently developing Lacripep, a bioactive proprietary proteoform of lacritin, for chronic treatment of the signs and symptoms of DED and recently completed a Phase I/II clinical trial of Lacripep in primary Sjögren’s Syndrome (pSS) patients, who experience the most severe form of DED. This trial represents the largest ophthalmic trial undertaken to date in the pSS patient population and is the first clinical study conducted with Lacripep as the active ingredient. Lacripep exhibited a highly statistically significant reduction in sign (inferior corneal staining) and symptom (burning and stinging). Importantly, it showed this improvement after only two weeks of dosing. Lacripep was well tolerated in this population and no serious treatment related adverse events were observed. TearSolutions continues to focus on the development of additional product candidates for DED. More information is available at www.tearsolutions.com About Lacripep Lacripep was patented by Dr. Gordon Laurie, a professor at the University of Virginia, based on his groundbreaking NIH funded research into the composition of human tears. He discovered lacritin and developed Lacripep, which represents a unique treatment modality, since it would be a naturally occurring protein replacement therapy to restore homeostasis in patients with DED, as well as representing a novel mechanism of action in DED. The intellectual property invented by Dr. Laurie is exclusively licensed to TearSolutions, Inc. from the University of Virginia Licensing and Ventures Group. Investors & Media

TearSolutions Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

TearSolutions Rank

  • When was TearSolutions founded?

    TearSolutions was founded in 2013.

  • Where is TearSolutions's headquarters?

    TearSolutions's headquarters is located at 315 Old Ivy Way, Charlottesville.

  • What is TearSolutions's latest funding round?

    TearSolutions's latest funding round is Convertible Note - IV.

  • How much did TearSolutions raise?

    TearSolutions raised a total of $28.43M.

  • Who are the investors of TearSolutions?

    Investors of TearSolutions include Pharmstandard International, VTC Innovation, LaunchCapital, University of Virginia, Virginia Venture Partners and 4 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.